These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27775938)

  • 21. Occult breast primary malignancy presenting as isolated axillary lymph node metastasis - early detection of primary site by 18F-FDG PET/CT.
    Soundararajan R; Naswa N; Karunanithi S; Walia R; Kumar R; Bal C
    Nucl Med Rev Cent East Eur; 2016; 19(B):5-7. PubMed ID: 27813620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
    Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
    J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance.
    Sohn YM; Hong IK; Han K
    J Ultrasound Med; 2014 Jun; 33(6):1013-21. PubMed ID: 24866608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How we read FCH-PET/CT for prostate cancer.
    Beauregard JM; Beaulieu A
    Cancer Imaging; 2016 Dec; 16(1):41. PubMed ID: 27923396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose High-resolution
    Ferdová E; Baxa J; Ňaršanská A; Hes O; Fínek J; Topolčan O; Ferda J
    Anticancer Res; 2018 Jul; 38(7):4145-4148. PubMed ID: 29970542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer.
    De Leiris N; Riou L; Leenhardt J; Vuillez JP; Djaileb L
    Clin Nucl Med; 2018 Dec; 43(12):e471-e472. PubMed ID: 30300202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
    Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
    Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study.
    Poulsen MH; Bouchelouche K; Gerke O; Petersen H; Svolgaard B; Marcussen N; Svolgaard N; Ogren M; Vach W; Høilund-Carlsen PF; Geertsen U; Walter S
    BJU Int; 2010 Sep; 106(5):639-43; discussion 644. PubMed ID: 20089104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidental Detection of Oxyphilic Papillary Thyroid Carcinoma by 18F-Fluorocholine PET/CT.
    Lalire P; Zalzali M; Garbar C; Bruna-Muraille C; Morland D
    Clin Nucl Med; 2016 Jun; 41(6):512-3. PubMed ID: 26914574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional value of
    van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
    Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The roles of
    Nakano Y; Noguchi M; Yokoi-Noguchi M; Ohno Y; Morioka E; Kosaka T; Takahashi T; Minato H
    Breast Cancer; 2017 Jan; 24(1):121-127. PubMed ID: 27015862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.